- Home
- GSBC vs DVAX Comparison
GSBC vs DVAX Comparison
Compare GSBC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- DVAX
- Stock Information
- Founded
- GSBC 1923
- DVAX 1996
- Country
- GSBC United States
- DVAX United States
- Employees
- GSBC N/A
- DVAX N/A
- Industry
- GSBC Major Banks
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- GSBC Finance
- DVAX Health Care
- Exchange
- GSBC Nasdaq
- DVAX Nasdaq
- Market Cap
- GSBC 676.3M
- DVAX 1.3B
- IPO Year
- GSBC N/A
- DVAX 2004
- Fundamental
- Price
- GSBC $62.71
- DVAX $9.41
- Analyst Decision
- GSBC Hold
- DVAX Buy
- Analyst Count
- GSBC 2
- DVAX 4
- Target Price
- GSBC $60.50
- DVAX $26.50
- AVG Volume (30 Days)
- GSBC 32.1K
- DVAX 1.8M
- Earning Date
- GSBC 10-15-2025
- DVAX 11-06-2025
- Dividend Yield
- GSBC 2.55%
- DVAX N/A
- EPS Growth
- GSBC 17.24
- DVAX N/A
- EPS
- GSBC 5.86
- DVAX N/A
- Revenue
- GSBC $224,299,000.00
- DVAX $316,268,000.00
- Revenue This Year
- GSBC N/A
- DVAX $23.23
- Revenue Next Year
- GSBC N/A
- DVAX $16.57
- P/E Ratio
- GSBC $10.70
- DVAX N/A
- Revenue Growth
- GSBC 4.82
- DVAX 26.66
- 52 Week Low
- GSBC $47.58
- DVAX $9.22
- 52 Week High
- GSBC $68.02
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- GSBC 55.27
- DVAX 33.66
- Support Level
- GSBC $62.76
- DVAX $9.51
- Resistance Level
- GSBC $63.81
- DVAX $9.94
- Average True Range (ATR)
- GSBC 0.92
- DVAX 0.29
- MACD
- GSBC -0.10
- DVAX -0.07
- Stochastic Oscillator
- GSBC 16.98
- DVAX 0.85
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.